Current chemotherapeutic regimens achieve CR in a large percentage of patients with AML. However, relapse after CR remains a significant problem. The presence of leukemic cells at levels too low to be detected by conventional microscopy, termed minimal residual disease (MRD), has been associated with an increased risk of relapse and shortened survival. Detection of MRD requires the use of highly sensitive ancillary techniques. Multi-color flow cytometric immunophenotyping is a sensitive method for quick and accurate detection of MRD. Use of this method in patient management may result in lower rates of relapse and improved survival, and is an effective means of assessing novel therapeutic agents. This method can be used in the vast majority of patients with AML, regardless of the immunophenotypic, cytogenetic and molecular genetic abnormalities present. Unfortunately, conflicting data regarding optimum methods of measurement and reporting, as well as the expertize required to interpret results have limited broad application of this technique. We provide a broad overview of this technique, including its advantages and limitations, and discuss the methods employed at our institution. We also review several possible areas of future investigation.
INTRODUCTION
AML is characterized by clonal expansion of myeloid precursors in the BM, peripheral blood and/or extramedullary tissues. 1 Current treatment regimens achieve CR in the majority of adult patients; however, approximately 65% of patients develop relapsed disease. 2, 3 Thus, there is a need to effectively identify which patients are at most risk for impending relapse. Low levels of leukemic cells, termed minimal residual disease (MRD), have been shown to correlate with an increased risk of relapse and shortened survival believed to be a major cause of relapse. 4 These cells are present at levels below the sensitivity of conventional microscopic examination and as such, their detection requires the use of sensitive ancillary techniques. Detection of MRD by multi-color flow cytometric immunophenotyping (MFC) has been shown to be useful in the detection and characterization of MRD. However, several important concepts must be understood in order to ensure optimal application of this technique in both the clinical and research settings so that the information provided can be translated into better patient outcomes.
THE CONCEPTS OF CR AND MRD
Following diagnosis, many AML patients undergo a cytarabineand anthracycline-based induction regimen followed by either chemotherapy-based consolidation or hematopoietic stem cell transplant (SCT). 2 Currently, pre-treatment factors such as age, cytogenetic risk score and mutational profile are used for risk stratification and clinical decision making. 1, 5, 6 However, the individual patient's response to therapy is also an important prognostic factor that should ideally be integrated into the risk stratification to help identify candidates who may benefit from alternative therapeutic agents or hematopoietic SCT. CR is the obvious desired response to induction therapy for all patients; however, current response criteria remain defined by clinical and microscopic data (Table 1) . 5 Nevertheless, it has long been understood that many patients who meet these criteria for CR will continue to have low levels of leukemic cells which are undetectable by conventional microscopic examination, and that persistence of this submicroscopic 'MRD' confers a higher risk of relapse. 4 Using these criteria, MRD represents any level of disease, which is detected by a technique that offers greater sensitivity than microscopy-based morphologic examination. Numerous methods have been described in the literature; however, MRD monitoring is still regarded as an investigational technique and has not been completely incorporated into current models of AML risk stratification. 1, 5, 6 The most commonly used methods fall into two general categories: (1) detection of cell surface immunophenotypic aberrations by MFC, (2) identification of MRD through molecular genetic techniques such as reverse transcriptase polymerase chain reaction (RT-PCR). Such techniques provide an extremely sensitive and specific method for detection of MRD by several means (Table 2 ). Several recent publications provide an excellent overview of both techniques, along with in-depth discussions of RT-PCR-based methods. [7] [8] [9] 
MULTI-COLOR FLOW CYTOMETRY-BASED DETECTION OF MRD IN AML
Research investigating the use of cell surface antigens to differentiate normal hematopoietic cells from leukemic blasts has spanned decades. In a review published in 1973, Harris rabbit-derived antiserum that was non-reactive with normal cells but highly reactive with leukemic blasts from patients with ALL and AML, indicating that antigenic differences existed between leukemic and non-leukemic cells. In 1975, Greaves 12 reviewed this subject and postulated that the use of immunofluourescent reagents and antibodies directed against leukemia-associated antigens could be used to detect residual leukemic cells and screen patients for early signs of relapse.
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Subsequent investigations failed to define an antigenic profile specific for AML; however, within two decades of Greaves 12 review, several groups had demonstrated expression of aberrant cell surface antigens on leukemic blasts which could be used to detect MRD. [13] [14] [15] [16] These antigenic alterations are referred to as leukemia-associated immunophenotypes' (LAPs or LAIPs) and are the principal basis of immunological MRD detection (Table 3) .
San Miguel et al. 4, 17 published an extensive list of LAPs and their frequencies. Using five-color flow cytometry, Al-Mawali et al. 18 found that asynchronous expression of antigens usually seen at distinct stages of myeloid maturation, (co-expression of early antigens such as CD34 and CD117 with more mature antigens such as CD15 or CD65), as well as cross-lineage antigen expression of lymphoid markers (CD2, CD7, CD10 and CD19) on myeloblasts were the most common types of LAPs.
One possible approach involves identification of one or more LAPs in the initial diagnostic sample of a patient with AML followed by construction of a patient-specific antibody panel for post-treatment evaluation. MFC is then used to document either the disappearance or persistence of the LAPs while simultaneously allowing the enumeration of aberrant cells. 19 While this method has been successfully used in several recent studies (Table 4) , multiple issues limit its utility for clinical diagnosis.
First, the immunophenotypic aberrancies of leukemic myeloblasts are not always stable in relapse specimens, a phenomenon referred to as 'immunophenotypic shift'. Changes in at least one antigen between diagnosis and relapse have been reported in up to 91% of AML patients. 20 These changes frequently involve increases in expression levels of myeloid (CD13, CD33) and stem cell antigens (CD34, CD117). 20, 21 In one study, 98% of patients had an aberrant blast population at relapse that was not noted in the original diagnostic specimen. 21 Such changes are referred to as 'population shifts'. These changes may be due to simple antigenic instability in the original leukemic clone, expansion of a preexisting small subclone and/or emergence of a new clone. Regardless, they represent a significant source of potential error if only LAPs detected at diagnosis are used to detect MRD. In addition, several 'LAPs' can in fact be seen at low frequency in normal BM (low-level expression of CD2, CD7, CD15 and CD56 expression are common examples). 9 Similar changes can be seen in benign, immature myeloid precursors during BM recovery as well as under the influence of exogenous growth factor therapy. Finally, access to initial, pre-treatment samples may be limited or unavailable and the construction of an individualized MRD panel for each patient may be impractical for many high-volume laboratories. Thus, while LAPs remain an important component of MFC-based MRD detection, they may be unreliable when used alone. Instead, we believe that LAPs are better used as part of a standardized, comprehensive MRD panel (see below). An alternative approach which avoids some of the above limitations is the so-called 'different from normal' method. This method is based on the principle that in normal hematopoiesis, the sequential expression of genes that regulates maturation and differentiation of progenitor cells also produces predictable alterations in their cell surface proteins. 22 Normal hematopoietic cells show a characteristic, sequential pattern of antigen expression for each lineage which can be visualized using MFC. 23 In most cases, it is possible to identify aberrant myeloblasts by their deviation from these normal patterns. For example, maturation in normal myeloblasts is accompanied by a gradual decline in CD13 and CD33 expression. 23 When CD13 and CD33 are plotted against each other, a characteristic 'diagonal' pattern is formed. Leukemic blasts with overexpression/underexpression of these markers will form clusters outside of this area, allowing for their identification and enumeration (Figures 1-3 ). This approach has been best documented in the pediatric population and identification of MRD using this method has been shown to be correlated with risk of relapse and shortened survival. 24, 25 This approach allows for the Patients with ⩾ 0.1% MRD after induction 1 or 2 had a worse EFS, mainly due to relapse MRD determination using microscopy, PCR and MFC showed poor overall correlation MRD measurement using MFC was best overall predictor of outcome Loken et al. Methods section states that patients with acute promyelocytic leukemia with t(15;17) were specifically excluded from analysis.
The sensitivity of MFC-based MRD detection is an important issue, especially in light of the availability of highly sensitive RT-PCR-based techniques. Sensitivity of MFC is in the range of 10 − 4 (refs 7,18) . However, the true sensitivity in any given individual assay depends on three factors: (1) the number of aberrant events used as a threshold of positivity, (2) the number of events acquired per staining tube, and most significantly, (3) the specificity of the LAP profile in a given AML patient in comparison to normal marrow elements. A commonly applied threshold requires 20 cells with an aberrant phenotype for a positive diagnosis of MRD, though more reliable quantitation is achieved with a threshold of 50 aberrant cells. Thus, for a limit of detection of 10 − 4 , at least 200 000 events must be acquired in order to identify 20 aberrant cells. However, this theoretical limit is impacted by the amount of low-level background 'noise', that is, cells with a 'LAP-like' phenotype representing normal or regenerating marrow (as previously discussed). Thus, the sensitivity for detection of a leukemic population with relatively few aberrant markers and relatively high levels of background 'noise' may only be in the range of 0.1% or even 1%. Detection and sensitivity is even more problematic in cases of AML with significant monocytic differentiation, as they often show fewer distinctive LAPs.
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PROGNOSTIC SIGNIFICANCE OF MULTI-COLOR FLOW CYTOMETRY-BASED MRD DETECTION IN AML
The prognostic significance of MRD detection using MFC has been examined in numerous studies performed in adults and children. 4, 17, 24, 25, [27] [28] [29] [30] [31] [32] [33] Overall, these studies demonstrate that MFC-detected MRD is prognostically significant in virtually all AML patients over a wide array of patient populations and treatment strategies (Table 4) . However, direct comparison of these studies is limited by variation in methodology, thresholds of positivity, patient population and treatment strategies. There have also been several contradictory findings regarding issues such as optimal timing of measurement (for example: post-induction vs post-consolidation) as well as cut-off values for MRD positivity. Despite this, several generalizations regarding the advantages and limitations of MRD measurement by MFC can be made.
ADVANTAGES OF MULTI-COLOR FLOW CYTOMETRY-BASED MRD DETECTION
MFC provides a relatively quick and inexpensive method of detecting MRD that is applicable in the vast majority of patients with AML These advantages are increasingly important as molecular genetic methods for MRD detection become increasingly available. Cytogenetic and molecular abnormalities are well-established risk factors in AML and, as previously mentioned, are amenable to MRD detection by RT-PCR-based methods. However, one of the main limitations of RT-PCR is that its use is limited to the subset of patients with an available molecular target. While approximately 20-35% of patients will have a leukemia-specific fusion transcript, detection of gene mutations such as NPM1 and FLT3 may allow RT-PCR-based MRD detection in up to 60-70% of patients. 6 With the increasing availability of whole-genome sequencing, it is likely that even more targets for molecular monitoring of MRD will become available. Nevertheless, different targets require different test platforms, not all of which are routinely available or standardized. Furthermore, leukemic blast populations are often composed of multiple subclones carrying a varying number of different mutations. After therapy, mutations may either be selectively expanded or replaced by subclones carrying additional mutations. Thus, molecular targets may be lost or gained at relapse, creating a 'moving target' for molecular methods. In addition, sensitivity will vary with the platform and molecular target. 8, 9, 34 In contrast, up to 95% of patients will have an aberrant immunophenotype available for MRD detection by MFC. 35 Thus, a single, standardized MFC panel can be uniformly applied to nearly all AML patients across all morphologic and cytogenetic sub-types with a level of sensitivity in the range of 10 − 3 -10 − 4 (refs 7,31). Furthermore, MFC detects leukemic cells showing any immunophenotypic deviation from normal hematopoietic precursors, including potential subclones with different immunophenotypic aberrancies than the original major blast population. As a result, the genetic and immunophenotypic instability of leukemic blasts is less problematic, because MFC allows the simultaneous tracking of multiple immunophenotypic aberrancies (multiple targets) in the same analysis. In addition, MFC can produce large amounts of data with a shorter turn-around time than most molecular methods. 34 Thus, after the blast count, the earliest available data regarding response to treatment will most likely be provided by MFC. It must be stated, however, that RT-PCR has been shown to be extremely efficient in patients with acute promyelocytic leukemia containing PML-RARα rearrangement and is the method of choice for this set of patients. MFC-based MRD detection provides objective data regarding relapse and survival As mentioned above, there have been contradictory findings regarding the most prognostically significant time point for measurement of MRD (that is, end of induction, end of consolidation, before or post SCT). However, what has consistently been shown is that when MRD is measured at almost any time point, its presence is correlated with an increased risk of relapse and worsened survival (Table 4 ). These observations support the notion that, regardless of the time point at which it is identified, patients with MRD have not achieved a full response to treatment and continue to have low levels of disease that increase the risk of relapse.
MRD detection provides an objective measure of efficacy for both traditional and novel therapeutic agents In their study of MRD-directed therapy, Rubnitz et al. 31 were able to use MRD to document a lack of difference between high-dose vs low-dose cytarabine in induction therapy. Furthermore, they documented a decrease or disappearance of MRD in patients treated with the anti-CD33 antibody gemtuzumab ozogamicin and showed improved outcomes in patients whose treatment was based on MRD-based risk stratification. Although gemtuzumab has recently been removed from the market, precluding further investigation of this agent, these results highlight the potential of MRD for use as a dynamic, almost 'real-time' measurement of therapeutic efficacy compared with more static factors such as cytogenetics and age.
LIMITATIONS OF MULTI-COLOR FLOW CYTOMETRY-BASED MRD DETECTION
The optimum threshold for positivity and time point for measurement has not been established A significant limitation of MRD measurement by MFC is the lack of a clear consensus regarding the level of aberrant cells that objectively defines MRD status as positive or negative. As discussed above, prognostically relevant findings have been demonstrated at a wide range of MRD thresholds and at a wide range of time points in therapy. Methods of quantitation have ranged from percentage of aberrant blasts as a percentage of total analyzed marrow cells, to log-difference of aberrant blast percentages before and after treatment. One study applied receiver-operating characteristics analysis to define a prognostically relevant threshold of 0.15% (ref 38). In contrast, some studies have shown that the presence of any amount of MRD is prognostically relevant. 25, 33 It is likely that different thresholds and best timing vary across different patient populations and are dependent on the underlying molecular abnormalities. Indeed, RT-PCR studies have shown that different molecular subgroups of AML show different relapse kinetics, and that the optimum time point of measurement depends on the type of molecular abnormality. 9, 34 Given the complex heterogeneity of AML in general, it is unlikely that a single cut-off value and time point for MRD can be uniformly applied to all AML patients. Thus, it is reasonable to propose that no amount of MFC-detected MRD, at any time point, should be regarded as 'negative'.
Lack of MRD may not predict maintenance of remission While the presence of MRD detected by flow cytometry may identify patients at increased risk of relapse, its absence has not been correlated with maintenance of remission. As previously mentioned, a receiver-operating characteristics-based threshold of 0.15% was recently used to characterize MRD positivity. 38 This threshold successfully divided patients into two groups with statistically significant differences in relapse and survival.
However, despite a fairly aggressive double-induction treatment regimen, 44% of patients classified as MRD-negative using this cut-off experienced relapse. Indeed, almost every study examining the prognostic relevance of MRD reports a percentage of MRDnegative patients who undergo relapse. These findings suggest that current methods are not sufficiently sensitive or alternatively, that MRD is not the only cause of relapse.
The measurement and reporting of MRD using MFC has not been standardized. As demonstrated above, the literature regarding MFC-based MRD detection is somewhat hampered by a lack of standardization. Most of this is unavoidable, due to the heterogeneous patient populations at each institution and the expected variation of measurement techniques and reagent antibody combinations. Variations in pre-analytic factors such as sequence of antibody addition and incubation times may also affect results. 19 Furthermore, the appearance of MRD on MFC can be subtle, with abnormal cells showing a spectrum of antigen expression intensity overlapping with that of regenerating normal precursors, introducing a certain amount of subjectivity to interpretation and reporting. 19 In fact, studies have shown that interpretation of aberrations can be operator dependent. 39 The European LeukemiaNet group has published recommendations regarding standardized pre-analytical steps and antibody combinations for the flow cytometric evaluation of acute leukemia. 40 However, even the use of standardized procedures may not eliminate small variations in fluorescence intensities, instrument performance and immunophenotypic profiles across different laboratories. 41 
DETECTION OF MRD BY MFC AT MD ANDERSON CANCER CENTER
AML MRD analyses at our institution are performed by a small group of pathologists who have received additional training and have demonstrated proficiency in their interpretation. FACSCanto II 8-color instruments (BD Biosciences, San Diego, CA, USA) are standardized daily using CS&T beads. In adequate specimens, a minimum of 200 000 events are acquired to achieve a potential sensitivity of at least 10 À 4 (0.01%; see caveats discussed above). In each tube, after excluding debris and doublets, an initial, wide gate is drawn around the CD45dim 'blast' and monocyte regions on a traditional CD45/side-scatter display. This is followed by back-gating to identify the CD34+ population (Figure 4) . Of the CD34+ cells, CD19 is used to remove normal immature precursor B cells (hematogones) from analysis. Both the CD34+ and CD34 − populations are separately evaluated in parallel, using a standardized, eight-color AML MRD panel which combines classic LAPs and the 'different from normal' approach. Numerous samples of normal BM were first assessed in order to establish a baseline for the pattern and expression level of various antigens before the implementation of patient testing. These samples, which are continuously updated, provide a normal control group for comparison in the case of subtle aberrancies. Mean fluorescence intensity of certain antigens such as CD13, CD34, CD38, CD45, CD117 and HLA-DR are also measured and compared with reference values derived from the normal control group.
The detection of ⩾ 20 clustered events with two or more aberrant markers, whether present in the original diagnostic sample or not, is considered positive for MRD. In certain instances, a positive diagnosis may still be rendered with only one aberrant marker if marked deviation from normal is present. The same is true if fewer than 20 events that show multiple, highly distinctive aberrations are detected. Extra caution is used for certain 'aberrancies' such as low levels of CD2 or CD7 expression which, as mentioned, may be seen in normal and regenerating marrow ( Figure 5 ). MRD levels are reported as an approximate percentage of total events.
The majority of AML patients in our institution undergo testing for MRD both after induction and consolidation as well as before and after allo-SCT. MFC-based MRD evaluation is done in conjunction with cytogenetic and molecular genetic-based methods. The results of all methodologies are used to guide treatment decisions as well as recruitment into clinical trials or to assess disease status prior to SCT. However, the frequency and timing of MRD measurement as well as any changes to therapy based on a positive result, is left to the discretion of the treatment team, often dictated by institutional treatment protocols.
FUTURE DIRECTIONS
Novel detection methods Flow cytometry provides multiple dimensions of information on each cell, producing an extensive data set for each cell that is analyzed. The limits of traditional gating and the human mind do not allow for the simultaneous evaluation of such a large amount of data. Thus, many groups have begun to investigate the use of computer algorithms to detect different cell populations. Although the majority of previous investigations involve the analysis of lymphoblasts, the overall results are encouraging. Pedreira et al. 42 used an automated, multivariate approach to evaluate flow cytometry data in the peripheral blood of 307 patients. This approach accurately identified lymphocyte subsets and was able to detect malignant B-cell populations. Fišer et al. 43 used an automated algorithm in combination with a novel technique based on hierarchical clustering analysis to successfully identify MRD in patients with acute lymphoblastic leukemia. A recent critical comparison of automated flow cytometry techniques found that such techniques compare well with manual techniques and traditional gating. 44 Although the use of such techniques for detection of MRD in AML remains limited, automated computer-based flow cytometric immunophenotyping is an exciting potential future area of investigation.
Novel applications An interesting use of flow cytometry involves the detection of 'leukemic stem cells' in AML. As most leukemic myeloblasts have limited capacity for self-renewal, it has been proposed that the maintenance of leukemia occurs via the self-renewal and proliferation of leukemic stem cells in a process that mimics normal hematopoiesis. 45 In fact, leukemia-inducing cells may consist of a hierarchy of several classes, each with a heterogeneous capacity for self-renewal and proliferation. 46 Thus, while chemotherapy may be able to effectively eliminate a rapidly expanding clonal population, it may not be able to completely eliminate the leukemic stem cell population from which it initiates. It is possible that the persistence of such cells results in MRD and eventually causes relapse. Similar to the hematopoietic stem cell, the leukemic stem cell population is believed to be a CD34 + / CD38 − population which is capable of self-renewal and proliferation. In some cases, these cells have been shown to express markers such as CLL-1, CD123, CD44, CD47 and CD96, and may also show many immunophenotypic aberrancies commonly seen in AML MRD. [47] [48] [49] [50] CD38 − population in initial and relapse BM specimens found that the initial blast population contained several subsets of blasts with heterogeneous mutational profiles. 3 In 5/6 patients who relapsed, the mutational profile of the blast population was similar to a minor, previously undetected subset of blasts in the initial specimen. Such findings support the notion that AML is formed from the selection and expansion of a small oligoclonal population of leukemic stem cells. Recently, an in vitro model showed that the combination of gemtuzumab and tipifarnib could be used to target the CD34 + /CD38
− population. 51 Studies using xenotransplantation models have shown that monoclonal antibodies directed against CD44, CD123 and CD47 may be useful for the eradication of leukemic stem cells. 49 Thus, MFC may be useful in identification of this potential source of MRD and may help to characterize the expression of potential therapeutic targets to eliminate it.
Next generation sequencing (NGS) is increasingly employed as a method for detecting MRD. Its widespread usage has been limited by the high cost at the present time. Other limiting factors include the stability of clone or subclones, as in RT-PCR-based assay, and interpretation of data. Technical improvement and cost reduction would likely bring a more feasible routine clinical application. While flow cytometry-and molecular-based methods each have unique advantages and limitations, it is likely that the combined use of both methods will yield the greatest sensitivity. Wilms tumor 1 gene (WT1) can be identified in the peripheral blood and BM of a majority of AML patients. 52, 53 Increased levels of WT1 detected by PCR have been shown to be a prognostically useful marker of MRD. [52] [53] [54] It has also been shown to be a predictor of relapse in AML patients who have undergone hematopoietic SCT. 55, 56 A recent study showed that the combined use of MFC and WT1 monitoring could distinguish between patients with high and low risk of relapse after hematopoietic SCT. 57 The authors reported higher sensitivity without a significant loss of specificity when both methods were used for MRD detection. Recently, a standardized WT1 assay was described and published by the European LeukemiaNet group. 58 Another study found that the use of post-consolidation MFCdetected MRD status in combination with pre-treatment karyotype and FLT3 mutational status improved risk stratification of AML patients. 59 A study of patients with core-binding factor AML found a similar improvement in risk stratification when post-consolidation MFC-detected MRD status was used in place of FLT3 and/or KIT mutational status. 60 These and other studies indicate that molecular and MFC-based MRD analysis will be increasingly used together in a patient-specific manner for improved risk stratification. The quality of such data is likely to be much improved by the use of NGS for MRD detection. Widespread use of NGS remains limited by such factors as cost and complexity. Furthermore, the previously mentioned presence of multiple subclones and clonal instability in AML also affects the results of NGS and adds to the complexity of interpretation. NGS for MRD detection has been recently implemented at our institution and it is hoped that time and experience will result in technical improvement, cost reduction, and eventual widespread use of this powerful technique.
Finally, MFC can be combined with a process called enzymatic amplification staining to measure extremely small amounts of cell surface proteins. Such techniques may be used to detect expression of cell cycle and apoptosis-related molecules in leukemic cells identified by flow cytometry. 61 Combining such techniques with traditional MRD detection may provide information regarding the viability of the residual blast population as well as possible cell cycle targets. Furthermore, detection of apoptosisrelated proteins in the residual blast population can be used as a measurement of the effectiveness of novel agents. 51 
RE-EVALUATION OF THE CONCEPTS OF CR AND MRD
As stated earlier, the concept of CR remains defined by microscopic examination and enumeration of blasts. In truth, morphologic enumeration of blasts in post-induction BM (socalled 'nadir' BM) at day 14 shows wide intra-observer variation. 62 For such patients, blast cut-offs may need to be raised as high as 15-22% in order to achieve acceptable levels of sensitivity and specificity. 63 Using multivariate analysis, Kern et al. 29 found that the percentage of blasts detected by morphology at day 16 showed no prognostic impact. 29 In addition, several studies have shown very poor correlation between morphologic blast counts and MFC-based MRD detection. Inaba et al. 32 found evidence of MRD by MFC ranging from 0.1-31% in 6.7% of patients found to be in morphologic CR. 32 Furthermore, in samples deemed indeterminate for residual disease by microscopy, 27.4% showed MRD ranging from 0.1-28.4%. Similarly, Loken et al. 25 found MRD levels ranging from 0.1 to >5% in 25% of patients who met morphologic criteria for CR. 25 Furthermore, 26% of patients who failed to achieve morphologic CR (blasts reported as 5-20%) lacked detectable MRD using MFC. These patients had a significantly better OS than those with MFC-detected MRD, suggesting that the blasts may have reflected normal myeloid precursors in early marrow regeneration. Such findings indicate that reliance on pure morphology may result in a significant number of patients receiving chemotherapy that might not require it, and a significant number with an incomplete response to therapy being withheld further treatment. Thus, it is clear that the current definition of CR is inaccurate and potentially misleading and that MRD data derived from MFC, RT-PCR, or preferably both, should be incorporated into the evaluation of posttreatment BM.
SUMMARY
The study of MRD has greatly increased the scope of knowledge regarding causes of relapse in AML. Techniques for detection of MRD in AML have evolved rapidly, beginning with animal-derived antisera and culminating in highly sensitive and complex multiparameter flow cytometry-and molecular-based techniques. Such methods are applicable in the majority of AML patients and have been proven to be more prognostically significant than traditional measurements of remission. Still, optimal employment of these methods is hampered by the paucity of prospective studies using standardized methods. With the exception of acute promyelocytic leukemia, an optimal method of MRD measurement remains to be determined for AML. Despite this, the use of MFC remains a useful tool and it is hoped that this review will encourage increased investigation of its use in the management of AML.
